Incyte revenue
Incyte's revenue was $5.14bn in fiscal 2025, up 21.2% on the year before. Since fiscal 2009 ($9.3m) it has grown at a compound 48.4% a year. Over the last twelve months it was $6.01bn.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9 | 170 | 94 | 297 | 355 | 511 | 754 | 1,106 | 1,536 | 1,882 | 2,159 | 2,667 | 2,986 | 3,395 | 3,696 | 4,241 | 5,141 | 6,011 |
| Growth on the year before | — | +>999% | −44.4% | +214.5% | +19.5% | +44.1% | +47.4% | +46.7% | +38.9% | +22.5% | +14.7% | +23.5% | +12.0% | +13.7% | +8.9% | +14.8% | +21.2% | — |
| Gross profit | — | — | — | — | — | — | — | 1,048 | 1,457 | 1,788 | 2,045 | 2,535 | 2,835 | 3,188 | 3,441 | 3,929 | 4,769 | 5,571 |
| Gross margin | — | — | — | — | — | — | — | 94.7% | 94.8% | 95.0% | 94.7% | 95.1% | 94.9% | 93.9% | 93.1% | 92.6% | 92.8% | 92.7% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Products | $4.4B | 85.1% | ▲ 20.3% |
| JAKAFI (part of Products) | $3.1B | 71.0% | ▲ 10.8% |
| Royalty (part of Products) | $637M | 14.6% | ▲ 9.9% |
| JAKAVI Royalty Revenues (part of Products) | $458M | 10.5% | ▲ 9.3% |
| Milestone and Contract Revenues (part of Products) | $150M | 3.4% | ▲ 248.8% |
| OPZELURA | $678M | 13.3% | ▲ 33.5% |
| NIKTIMVO (part of OPZELURA) | $152M | 22.4% | — |
| Olumiant Royalty (part of OPZELURA) | $145M | 21.3% | ▲ 6.7% |
| MINJUVIMONJUVI (part of OPZELURA) | $145M | 21.3% | ▲ 21.3% |
| ICLUSIG (part of OPZELURA) | $134M | 19.8% | ▲ 17.3% |
| ZYNYZ (part of OPZELURA) | $66.4M | 9.8% | ▲ 1983.2% |
| TABRECTA Royalty Revenues (part of OPZELURA) | $26.7M | 3.9% | ▲ 17.4% |
| Other Product Royalty Revenues (part of OPZELURA) | $7.9M | 1.2% | ▲ 262.9% |
| Pemazyre | $86.7M | 1.7% | ▲ 6.1% |
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $4.8B | 93.4% | ▲ 20.8% |
| Europe | $324M | 6.3% | ▲ 24.3% |
| Other Countries | $17.6M | 0.3% | ▲ 182.7% |
From Incyte's 10-K filed February 10, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Incyte | $6.01bn | 24.9% | 18.5% |
| Argenx SE | $4.15bn | 89.9% | — |
| Neurocrine Biosciences Inc | $3.70bn | 38.0% | 27.5% |
| Biogen | $10.30bn | 2.3% | 1.0% |
| Biomarin Pharmaceutical Inc | $3.41bn | 11.2% | 15.1% |
| Biontech SE | $3.24bn | 9.0% | — |
Compare with peers
- Argenx SE revenue
- Neurocrine Biosciences Inc revenue
- Biogen revenue
- Biomarin Pharmaceutical Inc revenue
- Biontech SE revenue
Head to head: ARGX vs INCYINCY vs NBIXBIIB vs INCY
More: Biotechnology stocks compared, Health Care sector, rankings of US companies